| HealthPartners | Oncology - chimeric antigen receptor/genetically | 2026-01-01 |
| HealthPartners | Oncology - copanlisib (Aliqopa™) – Minnesota Health | 2026-01-01 |
| HealthPartners | Oncology - ipilimumab (Yervoy®) | 2026-01-01 |
| HealthPartners | Oncology - ipilimumab (Yervoy®) – Minnesota Health | 2026-01-01 |
| HealthPartners | Oncology - lurbinectedin injection (Zepzelca™) – | 2026-01-01 |
| HealthPartners | Oncology - moxetumomab pasudotox-tdfk | 2026-01-01 |
| HealthPartners | Oncology - necitumumab (Portrazza®) | 2026-01-01 |
| HealthPartners | Oncology - nivolumab (Opdivo®) – Minnesota Health | 2026-01-01 |
| HealthPartners | Oncology - pertuzumab, trastuzumab, and | 2026-01-01 |
| HealthPartners | Oncology - tafasitamab-cxix (Monjuvi®) – Minnesota | 2026-01-01 |